Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Long-Term Investments: 2020-2025

Historic Long-Term Investments for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $19.0 million.

  • Lyell Immunopharma's Long-Term Investments fell 5.53% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 5.53%. This contributed to the annual value of $19.0 million for FY2024, which is 40.63% down from last year.
  • Lyell Immunopharma's Long-Term Investments amounted to $19.0 million in Q3 2025, which was down 5.28% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Long-Term Investments registered a high of $317.5 million during Q3 2021, and its lowest value of $10.0 million during Q1 2023.
  • Its 3-year average for Long-Term Investments is $23.3 million, with a median of $20.1 million in 2025.
  • As far as peak fluctuations go, Lyell Immunopharma's Long-Term Investments surged by 239.77% in 2021, and later tumbled by 95.54% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Long-Term Investments (Quarterly) stood at $283.5 million in 2021, then tumbled by 75.27% to $70.1 million in 2022, then tumbled by 54.36% to $32.0 million in 2023, then slumped by 40.63% to $19.0 million in 2024, then decreased by 5.53% to $19.0 million in 2025.
  • Its Long-Term Investments was $19.0 million in Q3 2025, compared to $20.1 million in Q2 2025 and $28.9 million in Q1 2025.